Cytomegalovirus in transplantation - Challenging the status quo

Clinical Transplantation

Volumn 21, Issue 2, 2007, Pages 149-158

  Fishman, Jay A ^a   Emery, Vincent ^b   Freeman, Richard ^c   Pascual, Manuel ^d   Rostaing, Lionel ^e   Schlitt, Hans J ^f   Sgarabotto, Dino ^g   Torre cisneros, Julian ^h   Uknis, Marc E ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c TUFTS MEDICAL CENTER   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e CHU RANGUEIL   (France)

^f UNIVERSITY OF REGENSBURG   (Germany)

^g UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^h HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Transplantation; Valganciclovir; Viremia

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIINFECTIVE AGENT; AZATHIOPRINE; CIDOFOVIR; COLONY STIMULATING FACTOR; COTRIMOXAZOLE; CREATININE; CYTOMEGALOVIRUS ANTIGEN PP65; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LUNG TRANSPLANTATION; META ANALYSIS; MORTALITY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROCONVERSION; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 33947723271     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00618.x     Document Type: Review

References (69)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998: 338: 1741.
2. Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol 2001: 54: 84.
3. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 2005: 365: 2105.
4. Ricart MJ, Malaise J, Moreno A, Crespo M, Fernandez-C ruz L, Euro-SPK study group. Cytomegalovirus: Occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial TransplanI 2005: 20 (Suppl. 2): ii25.
5. Fishman JA, Ramos E. In: Pereira BJG, Sayegh MH, Blake P, eds. Infection in Renal Transplant Recipients in Chronic Kidney Disease, Dialysis and Transplantation, 2nd edn. Philadelphia, PA: Saunders, 2005.
6. Cope AV, Sweny P, Sabin C et al. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 1997: 52: 200.
7. Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999: 190: 177.
8. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002: 186: 829.
9. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005: 5: 2894.
10. SiaI G, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000: 181: 717.
11. Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999: 1 (Suppl. 1): 8.
12. Rubin RH. Importance of CMV in the transplant population. Transpl Infect Dis 1999: 1 (Suppl. 1): 3.
13. Cobbs CS, Harkins L, Samanta M et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002: 62: 3347.
14. Danziger -Isakov LA, Dela Morena M, Hayashi RJ et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation 2003: 75: 1538.
15. Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. The Boston Center for liver transplantation CMVIG study group. Clin Infect Dis 1996: 23: 468.
16. Keenan RJ, Uknis ME, Pham SM et al. Mitogen responses of lymphocytes from lung transplant recipients - correlation with rejection and infection. Transplantation 1992: 54: 241.
17. Lemstrom KB, Koskinen PK, Bruning JH, Bruggeman CA, Lautenschlager IT, Hayry PJ. Effect of ganciclovir prophylaxis on cytomegalovirus-enhanced allograft arteriosclerosis. Transpl Int 1994: 7 (Suppl. 1): S383.
18. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 2003; 170: 998.
19. Valantine HA, Gao SZ, Menon SG et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999: 100: 61.
20. Z eevi A, U knis ME, S pichty KJ et al. Proliferation of cytomegalovirus-primed lymphocytes in bronchoalveolar lavages from lung transplant patients. Transplantation 1992: 54: 635.
21. Pouteil-Noble C, Ecochard R, Landrivon G et al. Cytomegalovirus infection - an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993: 55: 851.
22. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002: 2: 850.
23. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International valacyclovir cytomegalovirus prophylaxis transplantation study group. N Engl J Med 1999: 340: 1462.
24. Malaise J, Ricart MJ, Moreno A et al. Cytomegalovirus infection in simultaneous pancreas-kidney transplantation. Transplant Proc 2005: 37: 2848.
25. Valantine HA. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 2004: 4: 169.
26. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for liver transplantation CMVIG study group. Ann Intern Med 1997: 126: 275.
27. Hardinger KL, Schnitzler MA, Brennan DC et al. Cytomegalovirus increases the rate of graft loss after liver transplantation. Am J Transplant 2003: 3 (Suppl. 5); 523 (abstract 1445).
28. Slifkin M, Ruthazer R, Freeman R et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl 2005: 11: 1597.
29. Falagas ME, Snydman DR, Ruthazer R et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for liver transplantation CMVIG study group. Clin Transplant 1997: 11: 432.
30. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004: 4: 928.
31. Speir E. Cytomegalovirus gene regulation by reactive oxygen species. Agents in atherosclerosis. Ann NY Acad Sci 2000: 899: 363.
32. Squizzato A, Gerdes VE, Buller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005: 93: 403.
33. Weis M, Kledal TN, Lin KY et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004: 109: 500.
34. Basgoz N, Preiksaitis JK. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am 1995: 9: 901.
35. Harkins L, Volk AL, Samanta M et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002: 360: 1557.
36. Manez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease. J Infect Dis 1997: 176: 1462.
37. Razonable RR, van Cruijsen H, Brown RA et al. Dynamics of cytomegalovirus replication during pre-emptive therapy with oral ganciclovir. J Infect Dis 2003: 187: 1801.
38. Hodson EM, Barclay PG, Craig JC et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2005: 4: CD003774.
39. Snydman DR. Counterpoint: Prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: The case for prophylaxis. Clin Infect Dis 2005: 40: 709.
40. Sagedal S, Hartmann A, Rollag H. The impact of early cytomegalovirus infection and disease in renal transplant recipients. Clin Microbiol Infect 2005: 11: 518.
41. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005: 143: 870.
42. Legendre CM, Norman DJ, Keating MR, Maclaine GD, Grant DM. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: An economic evaluation. Transplantation 2000: 70: 1463.
43. Mauskopf JA, Richter A, Annemans L, Maclaine G. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. Pharmacoeconomics 2000: 18: 239.
44. Reischig T, Jindra P, Mares J et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 2005: 79: 317.
45. Geddes CC, Church CC, Collidge T et al. Management of cytomegalovirus infection by weekly surveillance after renal transplant: Analysis of cost, rejection and renal function. Nephrol Dial Transplant 2003: 18: 1891.
46. Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004: 189: 1615.
47. Uknis ME, Morrissey P, Simpson MA, Robidoux L, Crumpacker C. Extended use of valganciclovir is not associated with development of drug resistant CMV in kidney and pancreas transplant patients. Am J Transplant 2006: 6 (Suppl. 12): (abstract 1544).
48. Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The oral ganciclovir international transplantation study group [corrected]. Lancet 1997: 350: 1729.
49. G riffiths PD. Progress in the clinical management of herpesvirus infections. Antivir Chem Chemother 1995: 6: 191.
50. Noble S, Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998: 56: 115.
51. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000: 44: 2811.
52. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004: 4: 611.
53. Wiltshire H, Hirankarn S, Farrell C et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005: 44: 495.
54. Wiltshire H, Paya CV, Pescovitz MD et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005: 79: 1477.
55. Humar A, Mazzulli T, Moussa G et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R-transplant recipients. Am J Transplant 2005: 5: 1065.
56. Boeckh M. Impact of neutropenia on posttransplant management of cytomegalovirus. Clinician 2005: 22: 22.
57. Bonatti H, Cakar F, Hoefer D et al. Use of valgancyclovir in the prophylaxis, pre-emptive and directed therapy following solid organ transplantation. Am J Transplant 2004: 4 (Suppl. 8): 338 (abstract 659).
58. Sommadossi JP, Carlisle R. Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother 1987: 31: 452.
59. Knoll GA, Mac Donald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003: 14: 2381.
60. Schnitzler MA, Hardinger KL, Brennan DC. MMF dose modification following GI complications in renal transplantation. Am J Transplant 2004: 4 (Suppl. 8): 354 (abstract 719).
61. Turgeon N, Hovingh GK, Fishman JA et al. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Transpl Infect Dis 2000: 2: 15.
62. Armstrong WS, Kazanjian P. Use of cytokines in human immunodeficiency virus-infected patients: Colony-stimulating factors, erythropoietin, and interleukin-2. Clin Infect Dis 2001: 32: 766.
63. Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989: 320: 1381.
64. Duncan SR, Grgurich WF, Iacono AT et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994: 150: 146.
65. Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest 1999: 116: 1265.
66. Doyle A, Goral S, Grossman R, Bloom R. Lower risk of developing CMV disease in high risk patients with 6 months of prophylactic ganciclovir. Am J Transplant 2003: 3 (Suppl. 5): 504 (abstract 1376).
67. Keven K, Basu A, Tan HP et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004: 36: 3107.
68. Taber DJ, Ashcraft E, Baillie GM et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 2004: 6: 101.
69. Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004: 4: 1635.